08.20.19

Oxurion Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 in Combination with Ranibizumab for DME

Source: Oxurion NV

05.08.19

Oxurion Issues Financial and Business Update

Source: Oxurion NV

04.04.19

Oxurion NV Announces Full Enrollment of Its Phase 2 Trial Evaluating Combination of Anti-PlGF (THR-317) and Anti-VEGF (Ranibizumab) for the Treatment of DME

Source: Oxurion NV

09.20.18

Oxurion Enrolls First Patient in Phase 2 Study Evaluating THR-317 for Treatment of Idiopathic Macular Telangiectasia Type 1

Source: Oxurion

09.17.18

Oxurion to Present Scientific Findings Supporting Therapeutic Potential of THR-317 and THR-687 at EURETINA

Source: Oxurion NV

04.27.18

ThromboGenics Initiates Phase 2 Clinical Study Evaluating Anti-PlGF in Combination With Anti-VEGF for Treatment of DME

Source: ThromboGenics

View more stories